XML 86 R76.htm IDEA: XBRL DOCUMENT v3.24.0.1
Balance Sheet Components - Additional Information (Detail) - USD ($)
 3 Months Ended 12 Months Ended
Jul. 14, 2023
Sep. 30, 2023
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Jul. 31, 2021
Schedule of Available-for-sale Securities [Line Items]            
Other-than-temporary impairment loss     $ 0      
Net unbilled co-development revenue     0 $ 0    
Litigation settlement receivable     28,500,000      
Depreciation expense     9,518,000 10,017,000 $ 10,170,000  
API and bulk drug product price true-up     50,978,000 75,055,000    
Accrued litigation settlement     28,500,000      
Restructuring plan, expected reduction to workforce, percentage 32.00%          
Restructuring plan, non-recurring charges   $ 12,600,000 12,606,000 0 $ 0  
Cash payments for restructuring     8,900,000      
Accrued restructuring charges     3,700,000      
Cash and cash equivalents     113,688,000 155,700,000    
Eluminex Agreements [Member]            
Schedule of Available-for-sale Securities [Line Items]            
Aggregate consideration received for milestone and upfront payments     4,000,000.0     $ 8,000,000
AstraZeneca Agreements [Member]            
Schedule of Available-for-sale Securities [Line Items]            
Net unbilled co-development revenue     22,500,000 17,500,000    
Foreign subsidiaries [Member]            
Schedule of Available-for-sale Securities [Line Items]            
Cash and cash equivalents     $ 32,200,000 $ 92,500,000